{"title":"前列腺癌鉴别分子风险评估。","authors":"Benjamin Press, Michael Schulster, Marc A Bjurlin","doi":"10.3909/riu0787","DOIUrl":null,"url":null,"abstract":"<p><p>It is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of \"significant\" prostate cancer. Herein we discuss these tests and their clinical implications.</p>","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 1","pages":"12-18"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003298/pdf/RIU020001_012.pdf","citationCount":"8","resultStr":"{\"title\":\"Differentiating Molecular Risk Assessments for Prostate Cancer.\",\"authors\":\"Benjamin Press, Michael Schulster, Marc A Bjurlin\",\"doi\":\"10.3909/riu0787\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>It is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of \\\"significant\\\" prostate cancer. Herein we discuss these tests and their clinical implications.</p>\",\"PeriodicalId\":21185,\"journal\":{\"name\":\"Reviews in urology\",\"volume\":\"20 1\",\"pages\":\"12-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003298/pdf/RIU020001_012.pdf\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews in urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3909/riu0787\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3909/riu0787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Differentiating Molecular Risk Assessments for Prostate Cancer.
It is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of "significant" prostate cancer. Herein we discuss these tests and their clinical implications.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
